Loading quotes...
Forecast
The analysts' average price target is €231.43 (-24.79%). The median is €214.70 (-30.22%).
| Buy |
4 |
| Hold |
8 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 660.57m | 44.69% |
| Gross profit | 574.28m | 45.03% |
| Net profit | 133.23m | 33.84% |
| EBITDA | 172.63m | 45.16% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.27bn |
Number of shares | 37.54m |
52-week high/low | €300.22 - €140.74 |
| Dividends | No |
Beta | 0.88 |
P/E ratio | 83.48 |
PEG ratio | -2.54 |
P/B ratio | 18.38 |
P/S ratio | 17.21 |
Company profile
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
| Name | SHOCKWAVE MEDICAL DL-,001 |
| CEO | Douglas E. Godshall |
| Headquarters | Santa Clara,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 07/03/2019 |
| Employees | 1,468 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SWAV |
Frankfurt | 36M.F |
Düsseldorf | 36M.DU |
München | 36M.MU |
